

SPECTRUM PHARMACEUTICALS INC

Form 8-K

June 12, 2007

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of Report: June 8, 2007  
Spectrum Pharmaceuticals, Inc.  
(Exact name of Registrant as specified in its charter)**

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-28782**  
(Commission File  
Number)

**93-0979187**  
(I.R.S. Employer  
Identification No.)

**157 Technology Drive  
Irvine, California**  
(Address of principal executive offices)

**92618**  
(Zip Code)

**(949) 788-6700**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

SIGNATURE

---

**Table of Contents**

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 8, 2007, Dr. Dilip J. Mehta, a member of the Board of Directors of Spectrum Pharmaceuticals, Inc. (the Company ), informed the Company of his intention to retire from his position as a director of the Company, effective as of the date of the Company's 2007 annual meeting of stockholders, which the Company currently expects to occur in July 2007. Dr. Mehta's departure is pursuant to his decision to retire from various activities he was involved with, including his board membership with the Company, and is not related to any disagreement with the Company regarding the Company's operations, policies or practices.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SPECTRUM PHARMACEUTICALS, INC.

By: /s/ SHYAM KUMARIA  
Shyam Kumaria  
Vice President, Finance

Date: June 12, 2007